NLM Digital Collections

Search

Start Over Subjects Immunosuppressive Agents -- therapeutic use ✖Remove constraint Subjects: Immunosuppressive Agents -- therapeutic use Subjects United States ✖Remove constraint Subjects: United States

1. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
Subject(s):
Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

2. Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report

Author(s):
Tice, Jeffrey A., author
Agboola, Foluso, author
Herron-Smith, Serina, author
Chapman, Rick, (Of Institute for Clinical and Economic Review), author
Pearson, Steven D., author
Mandrik, Olena, author
Thokala, P. (Praveen), author
Fotheringham, James, (Of University of Sheffield), author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2021
Subject(s):
Antibodies, Monoclonal, Humanized
B-Cell Activating Factor -- antagonists & inhibitors
Calcineurin Inhibitors -- therapeutic use
Cyclosporine -- therapeutic use
Immunosuppressive Agents -- therapeutic use
Lupus Nephritis -- drug therapy
Treatment Outcome
United States